Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01186133

Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Percutaneous Transluminal Coronary Angioplasty Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Korean centres

Multiple Locations, South Korea

Location status: Recruiting

About this study

Consecutive patients receiving New DES without a mixture of other DES

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • coronary disease amenable to percutaneous coronary intervention (PCI)
  • no clinical and lesion limitations

Exclusion criteria

  • patients with a mixture of several DES
  • terminal illness with life expectancy less than 1 year
  • patients with cardiogenic shock

Treatment and study plan

Primary outcomes

  1. Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)

    Time frame: at 12 months post procedure

Secondary outcomes

  1. Death (all-cause and cardiac)

    Time frame: at 12 months and annually up to 5 years

  2. Myocardial infarction

    Time frame: at 12 months and annually up to 5 years

  3. Stent thrombosis

    Time frame: at 12 months and annually up to 5 years

  4. Target-lesion and target-vessel revascularization

    Time frame: at 12 months and annually up to 5 years

  5. Stroke

    Time frame: at 12 months and annually up to 5 years

  6. Procedural success

    Time frame: at 1 day

Study contacts

Contact information is provided by the study sponsor or research team.

Duk-Woo Park, MD

CONTACT

[email protected]

Seung-Jung Park, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Seung-Jung Park

Other

Collaborators

  • CardioVascular Research Foundation, Korea

Registry information

Official study title

Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Acronym: IRIS-DES

Important dates

Study start
2009
Primary completion
2030
Study completion
2030
First posted
Aug 23, 2010
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.